Filing Overview
Arcutis Biotherapeutics, Inc. filed a Form 8-K under Item 5.02 regarding a change in its executive officers. The earliest reported event was March 22, 2021; the filing was signed March 25, 2021, and states that the change was announced March 26, 2021.
Business Context and Reporting Period
Arcutis is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol ARQT. The filing concerns the retirement of Chief Financial Officer John Smither and the appointment of Scott Burrows as Chief Financial Officer and Principal Accounting Officer.
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, operating metrics, or other financial statement data.
Executive Changes and Compensation
- John Smither will retire as Chief Financial Officer effective March 31, 2021. He stated that the retirement is for personal reasons and is not related to any disagreement with the Company, management, or the Board.
- Scott Burrows, previously Arcutis’s Vice President of Finance since May 2019, will become Chief Financial Officer and Principal Accounting Officer effective April 1, 2021.
- Mr. Burrows will receive an annual base salary of $345,000 and is currently eligible for a discretionary annual performance bonus targeted at 40% of base salary.
- Mr. Burrows will receive a stock option award with a Black-Scholes value of $500,000. The exercise price will equal the Nasdaq closing price on the grant date, and the award will vest monthly over 48 months, subject to continued service.
- The Company will enter into severance and change-in-control and indemnification agreements with Mr. Burrows.
- Mr. Smither will serve in a transition and advisory capacity for up to two years following retirement under a transition and separation agreement approved March 25, 2021.
Material Changes, Outlook, and Risks
The principal material change is the transition in the Company’s chief financial and accounting leadership. The filing does not provide financial guidance, operating outlook, or management commentary regarding business performance.
Mr. Burrows’s severance arrangements provide, subject to execution of a release, continued salary and healthcare benefits if terminated without cause or resigns for good reason. Benefits generally extend for nine months outside a specified change-in-control period and for 12 months during the period beginning three months before and ending 18 months after a change in control. Change-in-control provisions also include a payment equal to his target annual incentive and accelerated vesting of eligible unvested equity awards.
The filing states that there are no arrangements or understandings involving Mr. Burrows’s selection, no family relationships with directors or executive officers, and no reportable related-party transactions under Item 404(a) of Regulation S-K.
Investor Verification Items
- Verify the effective dates of Mr. Smither’s retirement and Mr. Burrows’s appointments.
- Review subsequent filings for the final terms, grant date, share count, and fair value of the stock option.
- Assess the effect of the CFO transition and any related transition, separation, severance, or change-in-control obligations.
- Review subsequent periodic filings for financial results, liquidity, cash runway, and updated business guidance, which are not provided in this 8-K.